News Releases
Feb 21 2018
Avid Bioservices Selected as Commercial Manufacturer for Critical Enzyme Replacement Therapy by Enzyvant, a Subsidiary of Roivant Sciences
Feb 20 2018
Avid Bioservices Announces Closing of Public Offering of Common Stock
Feb 15 2018
Avid Bioservices Announces Pricing of Public Offering of Common Stock
Feb 14 2018
Avid Bioservices Announces Proposed Offering of Common Stock
Feb 12 2018
Avid Bioservices and Oncologie Enter Into Asset Assignment and Purchase Agreement for Avid's PS-Targeting Program Including Bavituximab
Jan 23 2018
Avid Bioservices to Present at NobleCon14
Jan 5 2018
Peregrine Pharmaceuticals Announces Name Change to Avid Bioservices as Part of Transition to Dedicated Contract Development and Manufacturing Organization (CDMO)
Jan 2 2018
Peregrine Pharmaceuticals to Present at Biotech Showcase 2018
Dec 26 2017
Peregrine Pharmaceuticals Announces Appointment of Roger J. Lias, Ph.D., as President and Chief Executive Officer
Dec 11 2017
Peregrine Pharmaceuticals Reports Financial Results for Second Quarter of Fiscal Year 2018 and Recent Developments